Unknown PHASE1 INTERVENTIONAL 1-arm NCT04887025

Exploratory Study of a Novel Oncolytic Vaccinia Virus RGV004 in the Treatment of Refractory/Relapsed B-cell Lymphoma

Exploratory Study of a Novel Oncolytic Vaccinia Virus Expressing Bispecific Antibody in the Treatment of Refractory/Relapsed B-cell Lymphoma

Sponsor: Hangzhou Rongu Biotechnology Co., Ltd.

Conditions Relapsed or Refractory B-cell Lymphoma

Interventions RGV004

Updated 6 times since 2021 Last updated: Feb 2, 2023 Started: Feb 8, 2022 Primary completion: Mar 15, 2023 Completion: Mar 15, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Relapsed or Refractory B-cell Lymphoma, this trial is ongoing. The trial is conducted by Hangzhou Rongu Biotechnology Co., Ltd. and has accumulated 6 data snapshots since 2022. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Apr 2025 — Present [monthly]

Unknown PHASE1

Status: Recruiting → Unknown
Sep 2024 — Apr 2025 [monthly]

Recruiting PHASE1
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1
Mar 2023 — Jul 2024 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
Oct 2021 — Mar 2023 [monthly]

Not Yet Recruiting PHASE1

▶ Show 1 earlier version

Jun 2021 — Oct 2021 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hangzhou Rongu Biotechnology Co., Ltd.
Second Affiliated Hospital, School of Medicine, Zhejiang University

Data source: Second Affiliated Hospital, School of Medicine, Zhejiang University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hangzhou, China